Crossmark

Cost-effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalemia in patients with chronic kidney disease or heart failure in Spain

Crossref DOI link: https://doi.org/10.1016/j.nefroe.2024.10.001

Published Print: 2024-09

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Alcázar-Arroyo, Roberto

Crespo-Leiro, María G

Bover, Jordi

Oliva, Juan

Sequera-Mutiozabal, Miren

Gradari, Simona

Martínez-López, Anisia

López-Chicheri, Blanca

Vidal-Vilar, Neus

Aceituno, Susana

Cobo, Marta
Funding

Funding for this research was provided by:

AstraZeneca
License Information

Text and Data Mining valid from 2024-09-01

Text and Data Mining valid from 2024-09-01

Version of Record valid from 2024-10-14
More Information

This article is maintained by: Elsevier

Article Title: Cost-effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalemia in patients with chronic kidney disease or heart failure in Spain

Journal Title: Nefrología (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.nefroe.2024.10.001

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.nefro.2024.02.006

Content Type: article

Copyright: © 2024 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Nefrología.

Document is current

Any future updates will be listed below